What's new in the antibiotic pipeline

Current Opinion in Microbiology

Volumn 2, Issue 5, 1999, Pages 475-482

  Lee, Ving J ^a   Miller, George H ^a   Yagisawa, Morimasa ^b  

^a Microcide Pharmaceuticals Inc   (United States)

^b Japan Antibiot Res A   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

3 [5 [4 (1 AMINO 2 CARBAMOYLETHYL)PHENYL] 3 PYRROLIDINYLTHIO] 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID; 3 [5 [4 (AMINOMETHYL)PHENYL] 3 PYRROLIDINYLTHIO] 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID; 6 (1 HYDROXYETHYL) 4 METHYL 3 [5 (4 METHYLAMINOMETHYLPHENYL) 3 PYRROLIDINYLTHIO] 7 OXO 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID; 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 3 (5 OXO 3 PYRROLIDINYLTHIO) 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID; 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 3 (5 OXO 3 PYRROLIDINYLTHIO) 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID PIVALOYLOXYMETHYL ESTER; 6 (1 HYDROXYETHYL) 4 METHYL 7 OXO 3 [1 (2 THIAZOLIN 2 YL) 3 AZETIDINYL] 1 AZABICYCLO[3.2.0]HEPT 2 ENE 2 CARBOXYLIC ACID PIVALOYLOXYMETHYL ESTER; 7 [[(2 AMINO 5 CHLORO 4 THIAZOLYL)(HYDROXYIMINO)ACETYL]AMINO] 3 [[3 [[(2 AMINOETHYL)THIO]METHYL] 4 PYRIDINYL]THIO] 8 OXO 5 THIA 1 AZABICYCLO[4.2.0]OCT 2 ENE 2 CARBOXYLIC ACID; A 181785; A 184656; A 241550; ANTIBIOTIC AGENT; CARBAPENEM DERIVATIVE; CEFMATILEN; CEPHALOSPORIN DERIVATIVE; CP 279107; CP 544372; CP 6679; DORIPENEM; E 1101; ERTAPENEM; HMR 3004; KR 21056; L 786392; ME 1209; RO 639141; SANFETRINEM; TELITHROMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ANTIMICROBIAL ACTIVITY; BACTERIAL INFECTION; COST MINIMIZATION ANALYSIS; NONHUMAN; REVIEW;

BACTERIA (MICROORGANISMS); THIA;

EID: 0032856369     PISSN: 13695274     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1369-5274(99)00003-X     Document Type: Review

References (86)

1. Andes D L-084. Curr Opin Anti-infect Invest Drugs. 1:1999;101-103.
2. Morrissey I KR-21056. Curr Opin Anti-infect Invest Drugs. 1:1999;108-110.
3. van Ogtrop ML CS-834. Curr Opin Anti-infect Invest Drugs. 1:1999;70-73.
4. Nishi T, Ishida Y, Sugita K, Ohtsuka M, Takemura M, Hayakawa I, Hayano T DZ-2640, a new oral carbapenem antibiotic, 1: structure activity relationships and in vitro activity. Abstracts of the 35th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1995 Sept 17-20; San Francisco. 1995;F133 American Society for Microbiology, Washington, DC.
5. Hohmura M, Tanaka M, Ishida H, Akasaka T, Mori S, Sato K, Hayano T, Hayakawa I DZ-2640, a new oral carbapenem antibiotic, 2: in vitro antimicrobial activity and β-lactamase stability of DU-6681, a parent compound of DZ-2640. Abstracts of the 35th Interscience Conference Antimicrobial Agents and Chemotherapy(ICAAC): 1995 Sept 17-20; San Francisco. 1995;F134 American Society for Microbiology, Washington, DC.
6. Sifaoui F, Varon E, Kitzis M-D, Gutmann L In vitro activity of sanfetrinem and affinity for the penicillin-binding proteins of Streptococcus pneumoniae. Antimicrob Agents Chemother. 42:1998;173-175.
7. Babini GS, Yuan M, Livermore DM Interactions of β-lactamases with sanfetrinem (GV 104326) compared to those with imipenem and with oral β-lactams. Antimicrob Agents Chemother. 42:1998;1168-1175.
8. Tamura S, Miyazaki S, Tateda K, Ohno A, Ishii Y, Matsumoto T, Furuya N, Yamaguchi K In vivo antibacterial activities of sanfetrinem cilexetil, a new oral tricyclic antibiotic. Antimicrob Agents Chemother. 42:1998;1858-1861.
9. Jiraskova N MEN 10700. Curr Opin Anti-infect Invest Drugs. 1:1999;117-119.
10. Neu HC, Chin NX, Labthavikul P The in-vitro activity of a novel penem FCE 22101 compared to other beta-lactam antibiotics. J Antimicrob Chemother. 16:1985;305-313.
11. Nord CE, Lindmark A, Person I Susceptibility of anaerobic bacteria to FCE 22101. Antimicrob Agents Chemother. 31:1987;831-833.
12. Mazzaglia G S-1090. Curr Opin Anti-Infect Invest Drugs. 1:1999;57-63.
13. Kawazoe K, Mikamo H, Sato Y, Hayasaki Y, Tamaya T In vitro activities of E1101, a novel oral cephalosporin, against bacterial causing infections in obstetric and gynecological patients. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F10 American Society for Microbiology, Washington, DC.
14. Watanabe Y, Hatano K, Wakai Y, Matsumoto Y, Morinaga C, Matsumoto S, Tawara S, Kawabata K, Yamamoto H, Takasugi Het al. FK-041, a new orally active cephalosporin: in vitro and in vivo antibacterial activity. Abstracts of the 36th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1996 Sept 15-18, New Orleans. 1996;F131 American Society for Microbiology, Washington, DC.
15. Matsumoto S, Sakamoto S, Yamamoto T, Maeda F, Tawara S, Azuma J, Matsumoto F, Kuwahara S FK-041, a new orally active cephalosporin: pharmacokinetics in animals and in healthy volunteers. Abstracts of the 36th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1996 Sept 15-18, New Orleans. 1996;F132 American Society for Microbiology, Washington, DC.
16. Andes D J-111,225. Curr Opin Anti-Infect Invest Drugs. 1:1999;111-113. A carbapenem that posses antibacterial activity against both MRSA and P. aeruginosa is described. It is unprecedented to have an antibiotic that possesses activity against both MRSA and Psuedomonas.
17. Rosen H, Hajdu R, Silver L, Kropp H, Dorso K, Kohler J, Sundelof JG, Huber J, Hammond GG, Jackson JJet al. Reduced immunotoxicity and preservation of antibacterial activity in releasable side-chain carbapenem antibiotic. Science. 283:1999;703-706.
18. van Ogtrop ML MK-826. Curr Opin Anti-Infect Invest Drugs. 1:1999;74-77.
19. Epstein-Toney JH S-4661. Curr Opin Anti-Infect Invest Drugs. 1:1999;64-69.
20. Kozawa O, Uematsu T, Matsuno H, Niwa M, Takiguchi Y, Matsumoto S, Minamoto M, Niida Y, Yokokawa M, Nagashima S, Kanamaru M Pharmacokinetic and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects. Antimicrob Agents Chemother. 42:1998;1433-1436.
21. ••].
22. ••].
23. ••].
24. ••].
25. ••], describe a broad-spectrum cephalosporin that also has anti-MRSA activity.
26. Pitout JDD MC-02,479. Curr Opin Anti-Infect Invest Drugs. 1:1999;104-107. A cephalosporin with activity against MRSA, Enterococcus spp. and sensitive- and resistant-S. pnueumoniae is described.
27. Ida T, Kurazono M, Yoshida T, Takase Y, Takayama Y, Kawabeta T, Hirano F ME1209 (CP6679), a new parenteral cephalosporin I. In vitro and in vivo activity against MRSA. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F12 American Society for Microbiology, Washington, DC.
28. Yoshida T, Ida I, Kurazono M, Kawabata T, Takayama Y, Takase Y, Hirano F ME1209 (CP6679), a new parenteral cephalosporin II. In vitro and in vivo activity against Pseudomonas aeruginosa. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F11 American Society for Microbiology, Washington, DC.
29. Barry AL, Fuchs PC, Brown SD Antipneumococcal activities of ketolide (HMR 3647), a streptogramin (quinupristin-dalfopristin), a macrolide (erythromycin), and a lincosamide (clindamycin). Antimicrob Agents Chemother. 42:1998;945-946.
30. Rosato A, Vicarini H, Bonnefoy A, Chantot J-F, Leclercq R A new ketolide, HMR 3004, active against streptococci inducibly resistant to erythromycin. Antimicrob Agents Chemother. 42:1998;1392-1396.
31. Roblin PM, Hammerschlag MR In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae. Antimicrob Agents Chemother. 42:1998;1515-1516.
32. Barry AL, Fuchs PC, Brown SD In vitro activities of the ketolide HMR 3647 against recent Gram-positive clinical isolates and Haemophilus influenzae. Antimicrob Agents Chemother. 42:1998;2138-2140.
33. Pankuch GA, Hoellman DB, Lin G, Bajaksouzian S, Jacobs MR, Appelbaum PC Activity of HMR 3647 compared to those of five agents against Haemophilus influenzae and Moraxella catarrhalis by MIC determination and time-kill assay. Antimicrob Agents Chemother. 42:1998;3032-3034.
34. Malathum K, Coque TM, Singh KV, Murray BE In vitro activities of two ketolides, HMR 3647 and HMR 3004, against Gram-positive bacteria. Antimicrob Agents Chemother. 43:1999;930-936.
35. Saez-Nieto JA, Vazquez JA In vitro activities of ketolides HRM 3647 and HRM 3004, levofloxacin, and other quinolones and macrolides against Neisseria spp. and Moraxella catarrhalis. Antimicrob Agents Chemother. 43:1999;983-984.
36. Ma Z, Or YS, Clark R, Wang S, Nilius AM, Bui M, Raney PM, Flamm RK, Chu DTW, Plattner JJ Synthesis and antibacterial activity of 6-O-substituted ketolides. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F126 American Society for Microbiology, Washington, DC.
37. Phan LT, Or YS, Chen Y, Chu DTW, Ewing P, Nilius AM, Bui MH, Raney PM, Hensy-Rudloff D, Mitten Met al. 2-Substituted tricyclic ketolides: new antibacterial macrolides - synthesis and biological activity. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F127 American Society for Microbiology, Washington, DC.
38. Clark RF, Or YS, Ma Z, Wang S, Chu DTW, Nilius AM, Bui MH, Raney PM, Henry RF, Plattner JJ Novel 6-O-substituted erythromycin A derivatives. Synthesis and antibacterial activity. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F125 American Society for Microbiology, Washington, DC.
39. Girard D, Mathieu HW, Girard AE, Menard CA, Su WG, Smyth KT, Rainville JP Pharmacokinetics and pharmacodynamics of CP-544,372, a new erthromycylamanine C4-carbamate, in murine pneumococcal pulmonary infections. Abstracts of the 38th Interscience Conference Antimicrobial Agents and (ICAAC): 1998 Sept 24-27; San Diego. 1998;F120 American Society for Microbiology, Washington, DC.
40. Girard D, Mathieu HW, Girard AE, Finegan SM, Menard CA, Su WG, Smyth KT, Rainville JP In vivo oral efficacy of CP-544,372, a new erythromycylamine C4-carbamate, against macrolide-resistant pneumococci and Haemophilus influenzae. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F121 American Society for Microbiology, Washington, DC.
41. Su WG, Smyth KT, Rainville JP, Kaneko T, Sutcliffe JA, Brennan LA, Duignan JM, Girard AE, Finegan SM, Cimochoski CR Novel erythromycylamine 4-carbamate antibacterial agents: synthesis and biological evaluation resulting in discovery of CP-544372. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F122 American Society for Microbiology, Washington, DC.
42. Anderson M, Bergeron J, Blair K, Brighty K, Cimochowski C, Finegan S, Fu W, Girard A, Girard D, Linde Ret al. In vitro and in vivo activity and mechanism of action of CP-279107, a C4 bis-aryl erythromycylamine derivative with potent activity against macrolide-resistant streptococci. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F128 American Society for Microbiology, Washington, DC.
43. Nicas TI, Zeckel ML, Braun DK Beyond vancomycin: new therapies to meet the challenge of glycopeptide resistance. Trends Microbiol. 5:1997;240-249. A review on small molecule strategies to overcome glycopeptide resistance.
44. Krivoy N BI-937. Curr Opin Anti-Infect Invest Drugs. 1:1999;120-124.
45. Johnson AP LY333327. Curr Opin Anti-Infect Invest Drugs. 1:1999;87-95. A review on a long-acting semi-synthetic glycopeptide with activity against vancomycin-resistant Enterococci. Completed Phase I studies.
46. Kenny GE, Cartwright FD Susceptibilities of human mycoplasmas to streptogramins: dalfopristin(RP-54476) and synercid (RP-59500). Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): 1997 Sept 28-Oct 1; Toronto. 1997;E160 American Society for Microbiology, Washington, DC.
47. Matsumura SG, Pong-Porter S, Trepeski L, De Azavedo J, Low DE The in vitro activity of recently developed antimicrobials against Streptococcus pneumoniae. Abstracts of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC): 1997 Sept 28-Oct 1; Toronto. 1997;E61 American Society for Microbiology, Washington, DC.
48. Maertens JA Ziracin. Curr Opin Anti-Infect Invest Drugs. 1:1999;49-56. A review on everninomicin, which has exquisite antibacterial activity against sensitive- and resistant-S. pnueumoniae, S. aureus and Enterococcus spp. (including VanA-, VanB- and VanC-resistance mechanisms), and coagulase-negative staphylococci. In Phase III trials.
49. Rybak MJ, Hershberger E, Moldovan T Comparative in vitro activity of daptomycin versus vancomycin, linezolid, and synercid against methicillin-resistant and susceptible staphylococci, vancomycin-intermediate susceptible Staphylococcus aureus (VISA) and vancomycin-susce. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;C146 American Society for Microbiology, Washington, DC.
50. Jacobus NV, McDermott L, Lonks JR, Boyce JM, Snydman DR In vitro activity of daptomycin against resistant Gram-positive pathogens. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F112 American Society for Microbiology, Washington, DC.
51. Oliver N, Andrew T, Silverman JA, Tally FP In vitro studies on resistance to lipopeptide antibiotic daptomycin. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F117 American Society for Microbiology, Washington, DC.
52. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother. 43:1999;738-744.
53. Yabe K, Murakami Y, Yamamoto N, Nishida S, Ikeuchi T, Sekiguchi M, Takemura M DC-756: A new methoxyquinolone: toxicological and pharmacokinetic evaluation. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F72 American Society for Microbiology, Washington, DC.
54. Takahaski H, Kawakami K, Sugita K, Ohki H, Kimura K, Miyauchi R, Sato K, Takemura M DC-756: A new methoxyquinolone: synthesis and in vitro activity of 7-(3-amino-4-substituted-pyrrolidin-1-yl) derivatives. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F73 American Society for Microbiology, Washington, DC.
55. Tanaka M, Namba K, Chiba M, Sato K DC-756: A new methoxyquinolone: in vitro antibacterial activity against clinical isolates. Abstracts of the 38th Interscience Conference Antimicrobial Agents and (ICAAC): 1998 Sept 24-27; San Diego. 1998;F74 American Society for Microbiology, Washington, DC.
56. Sakurai N, Hirayama F, Sano M, Uemori S, Moriguchi A, Yokoyama Y, Yamamoto K, Miyoshi M, Ikeda Y, Kawakita T Synthesis and anti-Helicobacter pylori activity of Y-34867, a new 7-morpholino-quinolone. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F85 American Society for Microbiology, Washington, DC.
57. Takahata M, Mitsuyama J, Yamashiro Y, Yonezawa M, Araki H, Todo Y, Minami S, Watamabi Y, Narita H In vitro and in vivo antimicrobial activities of T-3811ME, a novel des-F(6)-quinolone. Antimicrob Agents Chemother. 43:1999;1077-1084.
58. Ohshita Y, Hayashi N, Amano H, Hirao Y, Niino Y, Yazaki A, Kobayashi Y WQ-3034, A novel acidic fluoroquinolone: in vitro and in vivo antimicrobial activities. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F84 American Society for Microbiology, Washington, DC.
59. Roblin PM, Hammerschlag MR In vitro activity of a new quinolone, S-34109, against Chlamydia pneumoniae and C. trachomatis. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F75 American Society for Microbiology, Washington, DC.
60. Yoshizumi S, Domon H, Miyazaki S, Yamaguchi K In vivo activity of HSR-903, a new fluoroquinolone, against respiratory pathogens. Antimicrob Agents Chemother. 42:1998;785-788.
61. Bèbèar CM, Renaudin H, Boudjadja A, Bèbèar C In vitro activity of BAY 12-8039, a new fluoroquinolone, against mycoplasmas. Antimicrob Agents Chemother. 42:1998;703-704.
62. Roblin PM, Hammerschlag MR In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae. Antimicrob Agents Chemother. 42:1998;951-952.
63. Schmidt H, Dalhoff A, Stuertz K, Trostdorf F, Chen V, Schneider O, Kohlsdorfer C, Brück W, Nau R Moxifloxacin in the therapy of experimental pneumococcal meningitis. Antimicrob Agents Chemother. 42:1998;1397-1401.
64. Hoppe JE, Dalhoff A, Pfründer D In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, Trovafloxacin, and Ciprofloxacin. Antimicrob Agents Chemother. 42:1998;1868.
65. Kim M-Y, Paek K-S, Choo YS SB-265805 (LB20304a): Selectivity between bacterial DNA gyrase and human topoisomerase II. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy Washington, DC: American Society for Microbiology. 1998;F89.
66. •].
67. •].
68. •].
69. •].
70. •] provide in-depth data on a quinolone antibacterial with promising activity against some quinolone-resistant organisms.
71. Song JH, Lin JH, Yang JW, Lee H, Kim SW, Peck KR, Kim S, Lee NY Antipneumococcal activity of the novel quinolone CFC-222 compared with other drugs by MIC and time-kill. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F80 American Society for Microbiology, Washington, DC.
72. Fukuda H, Hori S, Hiramatsu K Antibacterial activity of gatifloxacin (AM-1155, CG5501, BMS-206584), a newly developed fluoroquinolone, against sequentially acquired quinolone-resistant mutants and the norA transformant of Staphylococcus aureus. Antimicrob Agents Chemother. 42:1998;1917-1922.
73. Ednie LM, Jacobs MR, Appelbaum PC Activities of gatifloxacin compared to those of seven other agents against anaerobic organisms. Antimicrob Agents Chemother. 42:1998;2459-2462.
74. Takei M, Fukuda H, Yasue T, Hosaka M, Oomori Y Inhibitory activities of gatifloxacin (AM-1155), a newly developed fluoroquinolone, against bacterial and mammalian Type II topoisomerases. Antimicrob Agents Chemother. 42:1998;2678-2681.
75. Ednie LM, Jacobs MR, Applebaum PC Comparative activities of clinafloxacin against Gram-positive and -negative bacteria. Antimicrob Agents Chemother. 42:1998;1269-1273.
76. Ji B, Lounis N, Maslo C, Truffot-Pernot C, Bonnafous P, Grosset J In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. Antimicrob Agents Chemother. 42:1998;2066-2069.
77. •].
78. •].
79. •] provide a discussion on the systematic search for equipotent quinolone carboxylic acid isoteres, 4H-4-oxoquinolizine carboxylic acids.
80. Oleksijew A, Meulbroek J, Ewing P, Jarvis K, Mitten M, Paige L, Tovcimak A, Nakkula M, Chu D, Alder JD In vivo efficacy of ABT-255 against drug-sensitive and -resistant Mycobacterium tuberculosis strains. Antimicrob Agents Chemother. 42:1998;2674-2677.
81. Hutchinson DK, Barbachyn MR, Hester JB, Emmert DE, Garmon SA, Reischer RJ, Stelzer LS, Zurenko GE, Ford CW Synthesis and antibacterial activity of azolylphenyloxazolidinones having nitrogen-bound five-membered heterocyclic rings. Abstracts of the 38th Interscience Conference Antimicrobial Agents and (ICAAC): 1998 Sept 24-27; San Diego. 1998;F137 American Society for Microbiology, Washington, DC.
82. Glenn MJ, Allwine DA, Hutchinson DK, Garmon SA, Reischer RJ, Barbachyn MR, Grega KC, Morris J, Graber DR, Hester JBet al. Substituent effects on antibacterial activity of novel highly potent nitrogen-bound azolylphenyl oxazolidiones. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F138 American Society for Microbiology, Washington, DC.
83. Gadwood RC, Walker EA, Thomasco LM, Barbachyn MR, Grega KC, Genin MJ, Zurenko GE, Ford CW Synthesis and antibacterial activity of azolylphenyl oxazolidinones having carbon-bound 1,3-thiazolyl rings. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F139 American Society for Microbiology, Washington, DC.
84. Bartel B, Endermann R, Guarnieri W, Habich D, Harter M, Kroll H-P, Raddatz S, Riedl B, Rosentretter U, Ruppelt Met al. Synthesis and antibacterial activity of novel heteroaryl oxazolidinones I. Benzoxazolone and benzthiazolone oxazolidinones. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F131 American Society for Microbiology, Washington, DC.
85. Wild H, Bartel S, Endermann R, Guarnieri W, Habich D, Harter M, Kroll H-P, Raddatz S, Riedl B, Rosentretter Uet al. Synthesis and antibacterial activity of novel heteroaryl oxazolidinones II: replacements of the N-acetyl moiety in several series. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F130 American Society for Microbiology, Washington, DC.
86. Endermann R, Bartel S, Guarnieri W, Habich D, Harter M, Kroll H-P, Raddatz S, Riedl B, Rosentretter U, Ruppelt Met al. Synthesis and antibacterial activity of novel heteroaryl oxazolidinones III: activities against clinically important gram-positive pathogens. Abstracts of the 38th Interscience Conference Antimicrobial Agents and Chemotherapy (ICAAC): 1998 Sept 24-27; San Diego. 1998;F129 American Society for Microbiology, Washington, DC.